Vaxil Bio Ltd. · TSXV:VXL
Vaxil Bio — Investor Presentation (January 2021)
15 slides from Vaxil Bio's investor presentation, January 2021
Slide 1: Directing Immunity Directly – January 2021
DIRECTING IMMUNITY DIRECTLY JANUARY 2021
Slide 2: Forward-looking statements
Forward-looking statements The information contained in this presentation is provided by Vaxil Bio Ltd. (“Vaxil”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Vaxil or other financial products.
Slide 3: Executive Summary
Executive Summary Vaxil is an Israeli biotechnology company developing novel immunotherapies including neoantigen-like signal peptides and antibodies to treat cancer and infectious diseases. Our experienced board and scientific team have access to world class medical centers and academia. Leading pl
Slide 4: Management and scientific team
David Goren, MBA Gadi Levin, CPA, MBA Yuval Avnir, PhD, MA Riva Kovjazin, MD, PhD CEO and Chairman CFO and Director Head of R&D Senior Scientist • Head, Pfizer Worldwide • Research Fellow, Dana-Farber • CFO, LabStyle Innovations Ltd Cancer Institute • Project leader, Center for Strategy and BD Clini
Slide 5: Directors and advisors
Ari S. Kellen, MD, MBA, Director • Strategic advisor and investor to early-stage innovative healthcare companies Ronny Pinkus, PhD, CMC • VP Mfg & Operations, Moebius Medical • Director, Theraclion • Head Analytical, InSight Biopharmaceuticals • Senior partner, McKinsey & Co. • EVP and GM, Bausch &
Slide 6: Market Cap, Cap Table and Funds Raised
(January 27, 2021) Market Cap Cap Table • CAD$40.2 M • Shares: 136.3 M Share price • Warrants: 11.3 M (exercise price CAD$0.10) • CAD$0.385 • Options: 6.6 M (avg exercise price CAD$0.10) Trading History Funds Raised (last 5 yrs) • 2016: RTO into Canadian primarily from individuals company (TSX.V) •
Slide 7: Pipeline: VaxHit platform and candidates
VaxHit™ Antigen Immune Preclinical Proprietary Clinical Mining validation development Algorithm Tuberculosis ID COVID-19 Vaccine Other candidates MUC1-SP Oncology Additional SPs P-ESBP mAb program
Slide 8: Targeting COVID-19 and solid tumors
Targeting COVID-19 01 (infectious disease) and solid tumors 05 Successful Phase 1/2a multiple myeloma clinical trial 02 VaxHit™ target ID for Orphan designation for signal peptides and mAbs 06 multiple myeloma (FDA / EMA) 03 Clinical stage immunotherapy 07 P-ESBP In-licensing 04 5 Patent families 08
Slide 9: Universal Neoantigen
Characteristics Vaxil Advantage Conserved No antigen loss short sequences Broad population Dense number Very high of epitopes immunogenicity • Wide HLA-subclasses • Universal – wide population • Cellular / humoral response • Robust immune response Specific to tumor Neoantigen • No immune tolerance c
Slide 10: COVID-19 programs
4 5 COVID-19 P-ESBP (BGU) (pending) 3 Antigen specific multiple epitope anti- 2 infectives Recombinant Abs + companion diagnostic for 1 ImMucin™ Antigen specific multiple epitope vaccines 10
Slide 11: COVID-19 vaccine approach using VaxHit
• Proprietary VaxHit™ tool identified signal peptides in SARS-CoV-2 (COVID-19) genome with high immunogenic potential • Unique approach: Complete immune response • Cellular (T cell) AND humoral (antibodies) • Targeting infected cells, not virus • Not susceptible to viral escape due to mutations • No
Slide 12: Achievement to date and next steps
Achievement to Date Next Steps • Candidate/s discovered using proprietary VaxHit™ tool • Pre-clinical "challenge" in vivo • IP secured experiment* • Preclinical efficacy experiments successfully demonstrated • Initiate GMP immunogenicity production, formulation including stability • ex vivo and in v
Slide 13: Preclinical immunogenicity experiments
Aim: Establish vaccine immunogenicity by assessing T cell proliferation. Method: Healthy donor peripheral blood mononuclear cells (PBMCs) stimulated by peptide- loaded autologous dendritic cells. Results: T cell proliferation was observed by flow cytometry for all candidate signal peptides, to varyi
Slide 14: Timeline
Timeline Q4 ‘20 Q1 ‘21 Q2 ‘21 H2 ‘21+ GMP Production, Formulation, Tox & Phase I/IIa*, COVID-19 Preclinical studies pre-IND / IND Optimization Peptide and Solid Tumor Anti-metastatic readout, Solid Tumor preclinical Oncology polymer experiments formulation, optimization, Ph I prep manufacturing (pre
Slide 15: Thank You
Thank You